NIAIDs' strategic plan for CARB-X and resources for development of anti-infectives to be discussed at SMi event
SMi Group reports: Study of Antimicrobial Resistance is a Priority for NIAID. Tina Guina, Therapeutics Development Project Officer at NIAID and a member of CARB-X’s Advisory Board to present at SMi's Superbugs & Superdrugs USA Conference (November 12 - 13, New Jersey).
- (1888PressRelease) June 27, 2018 - To address the growing problem of AMR, NIAID is funding and conducting research on many aspects of antimicrobial (drug) resistance, including basic research on how microbes develop resistance, new and faster diagnostics, and clinical trials designed to find new vaccines and treatments effective against drug-resistant microbes. [1]
One of the initiatives that NIAID has been involved in since its inception is the Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) - a public-private partnership that takes a novel consortium approach to developing new therapeutics, vaccines, diagnostics, and devices to fight antibiotic-resistant bacteria. With more than $500 million to invest between 2016 and 2021, CARB-X funds the best science from around the world.
Tina Guina, Therapeutics Development Project Officer at NIAID and a member of CARB-X’s Advisory Board, which ensures the highest scientific standards in evaluating applications for CARB-X funding - will be presenting at SMi's Superbugs & Superdrugs USA Conference (November 12 - 13, New Jersey).
Tina will be sharing with event participants NIAIDs' strategic plan for CARB-X and support for development of novel therapeutic classes; looking into overlapping funding strategies and a broad spectrum of preclinical and clinical services that educe product development risk; and analyse current funding and partnership opportunities for development of antibacterials.
SMi Superbugs & Superdrugs USA Conference programme will also feature presentations from Mark Albrecht on BARDAs' partnering with the industry to stimulate innovations and Evan Hecker of Spero Therapeutics on CMC strategies for novel antibiotic drug development
Further details at http://www.superbugs-usa.com/1888
Twitter - ( @ ) SMIpharm & #smibugs
LinkedIn - SMi Pharma
CONTACT:
+44 (0)20 7827 6000
ldurneva ( @ ) smi-online dot co dot uk
Superbugs & Superdrugs USA Conference| November 12 – 13, 2018 | New Jersey
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam